Kezar Life Sciences (KZR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Election of three directors: Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., and Courtney Wallace, with board recommendation to vote for all nominees.
Advisory vote on executive compensation (say-on-pay), with board recommendation to vote for.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2025, with board recommendation to vote for.
Board of directors and corporate governance
Board recommends all director nominees for election at the 2025 annual meeting.
Executive compensation and say-on-pay
Advisory vote on compensation for named executive officers is included as a voting item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kezar Life Sciences
- Zetomipzomib achieved durable, steroid-sparing remission in refractory AIH, supporting further trials.KZR
Q4 2024 & Study Result27 Dec 2025 - Biotech seeks $400M to advance immune disease drug, leveraging strong governance and flexible funding.KZR
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.KZR
Proxy Filing2 Dec 2025 - Net loss narrowed in Q3 2025 amid restructuring, strategic review, and major cost reductions.KZR
Q3 202512 Nov 2025 - Zidomipzomib delivers promising remission rates in refractory AIH, with pivotal trial plans advancing.KZR
Jefferies Global Healthcare Conference 202510 Nov 2025 - Net loss narrowed in Q2 2024; zetomipzomib prioritized and cash runway extends 12 months.KZR
Q2 202412 Oct 2025 - Net loss narrowed, liquidity strong, and focus shifts to autoimmune hepatitis after trial termination.KZR
Q3 202412 Oct 2025 - FDA lifted clinical hold on zetomipzomib; net loss narrowed, but more funding will be needed.KZR
Q2 202513 Aug 2025 - Zetomipzomib achieved durable, steroid-sparing remissions in autoimmune hepatitis with strong safety data.KZR
Corporate Presentation7 Jul 2025